Loading...
Edwards Lifesciences Community
NYSE:EW Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 62 Fair Values set on narratives written by author
Community Investing Ideas
Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead
Key Takeaways Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share. Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.Read more
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
AN
US$93.94
7.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
9.88% p.a.
Profit Margin
24.03%
Future PE
34.57x
Share price in 2028
US$117.3
